Back to Journals » Biologics: Targets and Therapy » Volume 6 » default
![](https://www.dovepress.com/cr_data/cache/journal_image/8/cope/thumb_100_1000_100.jpg)
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (511)
- Volume 18, 2024 (15)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 6, 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clofilium inhibits Slick and Slack potassium channels
Tejada MA, Stolpe K, Meinild AK, Klaerke DA
Biologics: Targets and Therapy 2012, 6:465-470
Published Date: 13 December 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70
Orme ME, MacGilchrist KS, Mitchell S, Spurden D, Bird A
Biologics: Targets and Therapy 2012, 6:429-464
Published Date: 17 December 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis
Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ
Biologics: Targets and Therapy 2012, 6:417-427
Published Date: 3 December 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Limited cross-reactivity of mouse monoclonal antibodies against Dengue virus capsid protein among four serotypes
Noda M, Masrinoul P, Punkum C, Pipattanaboon C, Ramasoota P, Setthapramote C, Sasaki T, Sasayama M, Yamashita A, Kurosu T, Ikuta K, Okabayashi T
Biologics: Targets and Therapy 2012, 6:409-416
Published Date: 26 November 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer
Smaldone MC, Chen DY, Yu JQ, Plimack ER
Biologics: Targets and Therapy 2012, 6:395-407
Published Date: 19 November 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
Wojciechowski D, Vincenti F
Biologics: Targets and Therapy 2012, 6:385-393
Published Date: 2 November 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Role of CD44 as a marker of cancer stem cells in head and neck cancer
Trapasso S, Allegra E
Biologics: Targets and Therapy 2012, 6:379-383
Published Date: 1 November 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical use of biologics in vasculitis syndromes
Paroli M
Biologics: Targets and Therapy 2012, 6:371-378
Published Date: 25 October 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
D'Ambrosio R, Aghemo A, Colombo M
Biologics: Targets and Therapy 2012, 6:363-370
Published Date: 18 October 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
Ippoliti G, D'Armini AM, Lucioni M, Marjieh M, Viganò M
Biologics: Targets and Therapy 2012, 6:355-362
Published Date: 4 October 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
Wiesik-Szewczyk E, Olesinska M
Biologics: Targets and Therapy 2012, 6:347-354
Published Date: 26 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Nguyen KS, Neal JW
Biologics: Targets and Therapy 2012, 6:337-345
Published Date: 25 September 2012
![Noteworthy comment: Asthma is currently affecting about 235 million people, and is the most common chronic disease in children. It is now well appreciated that asthma is not a simple disease. Reclassifying asthma with identification of sub-phenotypes has great impacts on choosing appropriate therapeutic approaches for improved treatment outcomes. It suggests that proper target should be chosen for individualized therapy. Accordingly, careful patient profiling and selection for clinical trials are extremely important. Moreover, many times, surrogate markers have to be used in clinical practice. This manuscript provided an excellent instruction of how to wisely choose appropriate biomarker(s) for patient classification and proper target(s) for improved therapy.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Lebrikizumab in the personalized management of asthma
Thomson NC, Patel M, Smith AD
Biologics: Targets and Therapy 2012, 6:329-335
Published Date: 14 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The role of epigenetic mechanisms and processes in autoimmune disorders
Greer JM, McCombe PA
Biologics: Targets and Therapy 2012, 6:307-327
Published Date: 6 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
OnabotulinumtoxinA in the treatment of neurogenic bladder
Gulamhusein A, Mangera A
Biologics: Targets and Therapy 2012, 6:299-306
Published Date: 28 August 2012
![Noteworthy comment: This paper reviews publically-available gene expression array data and characterizes luminal B cancer as a unique subtype of breast cancer that has a distinct biology from luminal A cancer. Breast cancer is a highly heterogeneous disease and the difficulty with its molecular classification using methods such as hierarchical clustering is making the distinction between subsets within the major classes. Inevitably there is overlap in genotypes and so practically, clinical utility is achieved by categorisation of patients into good and poor prognosis. It remains an ideal to be able to do this for all breast cancer patients at different stages of their disease using techniques compatible with current procedures.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The molecular profile of luminal B breast cancer
Creighton CJ
Biologics: Targets and Therapy 2012, 6:289-297
Published Date: 24 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Kobrynski L
Biologics: Targets and Therapy 2012, 6:277-287
Published Date: 24 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Castration-resistant prostate cancer: potential targets and therapies
Parray A, Siddique HR, Nanda S, Konety BR, Saleem M
Biologics: Targets and Therapy 2012, 6:267-276
Published Date: 17 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Emerging role of multikinase inhibitors for refractory thyroid cancer
Perez CA, Arango BA, Velez M, Raez LE, Santos ES
Biologics: Targets and Therapy 2012, 6:257-265
Published Date: 8 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
New developments in the management of hepatitis C virus infection: focus on boceprevir
Berenguer M, López-Labrador FX
Biologics: Targets and Therapy 2012, 6:249-256
Published Date: 3 August 2012
![Noteworthy comment: This study demonstrates that viral neutralizing activities (VN) of human intravenous immunoglobulin (IVIG) against the Influenza A H2N2 virus, also known as the Asian flu, correlates with the history of infection and vaccine program of the donating population in Japan. This study demonstrates that evaluation of antibody titers in donated](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010
Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K
Biologics: Targets and Therapy 2012, 6:245-247
Published Date: 27 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical utility of targeted treatments in the management of epithelial ovarian cancer
Twu C, Han ES
Biologics: Targets and Therapy 2012, 6:233-244
Published Date: 26 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cetuximab and biomarkers in non-small-cell lung carcinoma
Patil N, Abba M, Allgayer H
Biologics: Targets and Therapy 2012, 6:221-231
Published Date: 13 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Hepatocellular carcinoma: natural history, current management, and emerging tools
Tinkle CL, Haas-Kogan D
Biologics: Targets and Therapy 2012, 6:207-219
Published Date: 17 July 2012
![Noteworthy comment: This study demonstrates that halving the dose of adalimumab used for the treatment of psoriatic arthritis (PsA) maintains drug efficacy, reduces drug exposure risks and affords cost savings. Clinical remission was achieved in a high percentage of patients with early PsA. In contrast to patients with rheumatoid arthitis, a high proportion of PsA patients maintained remission over a long-term follow-up.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2012, 6:201-206
Published Date: 12 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
Kekow J, Mueller-Ladner U, Schulze-Koops H
Biologics: Targets and Therapy 2012, 6:191-199
Published Date: 2 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The effect of erythropoietin on normal and neoplastic cells
Elliott S, Sinclair AM
Biologics: Targets and Therapy 2012, 6:163-189
Published Date: 27 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
Jones G, Darian-Smith E, Kwok M, Winzenberg T
Biologics: Targets and Therapy 2012, 6:155-161
Published Date: 2 July 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Ovarian cancer: emerging molecular-targeted therapies
Sourbier C
Biologics: Targets and Therapy 2012, 6:147-154
Published Date: 20 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Metastatic gastric cancer – focus on targeted therapies
Meza-Junco J, Sawyer MB
Biologics: Targets and Therapy 2012, 6:137-146
Published Date: 20 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Emerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease
Kapoor S
Biologics: Targets and Therapy 2012, 6:135-136
Published Date: 6 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
Bradley GM, Oliva-Hemker M
Biologics: Targets and Therapy 2012, 6:125-134
Published Date: 5 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms
Wilson HL
Biologics: Targets and Therapy 2012, 6:117-123
Published Date: 7 May 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Exacerbation of collagen induced arthritis by Fcγ receptor targeted collagen peptide due to enhanced inflammatory chemokine and cytokine production
Szarka E, Neer Zs, Balogh P, Ádori M, Angyal A, Prechl J, Kiss E, Kövesdi D, Sármay G
Biologics: Targets and Therapy 2012, 6:101-115
Published Date: 12 April 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
Brown-Glaberman U, Stopeck AT
Biologics: Targets and Therapy 2012, 6:89-99
Published Date: 12 April 2012
![Noteworthy comment: This study provides evidence that activation of natural killer cells can be used as an early predictor of response in patients with rheumatoid arthritis treated with rituximab. Activation of natural killer cells, measured 3 months after the first rituximab course, significantly correlated with clinical response at 6 months and 1 year, independently from other clinical variables. These results support the current scientific thought that natural killer cells may be effectors of antibody dependent cell mediated cytotoxicity induced by monoclonal antibody therapies, such as rituximab.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M
Biologics: Targets and Therapy 2012, 6:83-87
Published Date: 11 April 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Natural killer cells: role in local tumor growth and metastasis
Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N
Biologics: Targets and Therapy 2012, 6:73-82
Published Date: 5 April 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes
Bolton K, Segal D, Walder K
Biologics: Targets and Therapy 2012, 6:67-72
Published Date: 2 April 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Role of vandetanib in the management of medullary thyroid cancer
Brassard M, Rondeau G
Biologics: Targets and Therapy 2012, 6:59-66
Published Date: 8 March 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Stem cell-mediated osteogenesis: therapeutic potential for bone tissue engineering
Neman J, Hambrecht A, Cadry C, Jandial R
Biologics: Targets and Therapy 2012, 6:47-57
Published Date: 9 March 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
Heslet L, Nielsen JD, Nepper-Christensen S
Biologics: Targets and Therapy 2012, 6:37-46
Published Date: 6 March 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S
Biologics: Targets and Therapy 2012, 6:31-35
Published Date: 1 February 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Eribulin mesylate in the treatment of metastatic breast cancer
Jain S, Cigler T
Biologics: Targets and Therapy 2012, 6:21-29
Published Date: 11 January 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Monoclonal antibodies and Fc fragments for treating solid tumors
Eisenbeis AM, Grau SJ
Biologics: Targets and Therapy 2012, 6:13-20
Published Date: 5 January 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I
Biologics: Targets and Therapy 2012, 6:5-12
Published Date: 29 December 2011
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Prevalence of OmpK35 and OmpK36 porin expression in beta-lactamase and non-beta-lactamase-producing Klebsiella pneumoniae
Shakib P, Ghafourian S, Zolfaghary MR, Hushmandfar R, Ranjbar R, Sadeghifard N
Biologics: Targets and Therapy 2012, 6:1-4
Published Date: 22 December 2011